

Non-alcoholic steatohepatitis: An update in pathophysiology, diagnosis and therapy

Hossein Khedmat^{1*}, Saeed Taheri²

¹ Baqiyatallah Research Center for Gastroenterology and Liver Disease, Baqiyatallah University of Medical Sciences, Tehran, IR Iran

² Dr. Taheri Medical Research Group, Tehran, IR Iran

ARTICLE INFO

Article Type:
Review Article

Article history:
Received: 23 May 2010
Revised: 14 Jul 2010
Accept: 27 Aug 2010

Keywords:
Non - alcoholic steatohepatitis
Diagnosis
Therapy

ABSTRACT

Non-alcoholic steatohepatitis (NASH), first described by Ludwig et al, in 1980, is a stage in the wide spectrum of non-alcoholic fatty liver diseases (NAFLDs) and one of the leading causes of chronic liver disease. Several scientists have tried to more distinctly discover and describe different aspects of NASH. In contrast with its counterpart in the NAFLDs—the NAFL—NASH consists of inflammation as well as necrosis in the liver tissue resulting in a poor outcome. NASH is also a known etiology for cryptogenic liver cirrhosis. Evidence suggests that cirrhosis developing due to NASH have a relatively worse outcome compared to that of hepatitis C-related cirrhosis. In this review article, we try to review and present all relevant articles about NASH.

© 2011 Kowsar M.P.Co. All rights reserved.

► Implication for health policy/practice/research/medical education:

The incidence of NASH is gradually increasing due to increasing in the risk factors. This review article endeavors to collect some important pathophysiological aspects of the disorder for attention of nutritionists, general practitioners and internists.

► Please cite this paper as:

Khedmat H, Taheri S. Non-alcoholic steatohepatitis: An update in pathophysiology, diagnosis and therapy. *Hepat Mon.* 2011;11(2):74-85.

Background

Non-alcoholic fatty liver diseases (NAFLDs) is a health dilemma for the recent three decades provoking quite less concerns in the past (1, 2). However, nowadays, its prevalence has grown to 30% in the United States general population and like other gastrointestinal disorders it also grew in developing countries (3). Non-alcoholic steatohepatitis (NASH), first described by Ludwig et al. in 1980, is a stage in the wide spectrum of NAFLDs and one of the leading causes of chronic liver disease (4). Powell and colleagues (5) recommended the following diagnostic criteria for NASH: a liver biopsy specimen that shows moderate to gross macrovesicular fatty degeneration with inflammation (lobular or portal) with or without Mallory hyaline bodies, fibrosis, or cirrhosis, convincing evidence of negligible alcohol consumption (<40 g of ethanol per week) that includes a detailed history taken

by three physicians independently and interrogation of family members and local medical practitioners. Results of random blood assays for the estimation of ethanol levels or of desialylated transferrin, a marker of alcohol consumption, should be negative, absence of serologic evidence of previous infection with hepatitis B virus or a clinical course that hepatitis C. In contrary to its counterpart in the NAFLDs—the NAFL—NASH consists of inflammation and necrosis in the liver tissue and has a poor outcome (6). NASH is also a known etiology for cryptogenic liver cirrhosis. After development of cirrhosis, steatosis disappears in the liver tissues leading to an underdetermined diagnosis of the underlying disease in cirrhotic patients (7, 8). According to a study by Ratziu, et al (9), cirrhosis developed due to NASH has a relatively worse outcome than that due to hepatitis C in one study. It can lead to hepatocellular carcinoma (7, 9-11). In this article, we try to review and present all relevant articles about NASH.

Methods

Search for articles were performed through Medline and Google Scholar using the keywords “non-alcoholic steato-

* Corresponding author at: Hossein Khedmat, Baqiyatallah Research Center for Gastroenterology and Liver Disease, Baqiyatallah University of Medical Sciences, Mollasadra Ave, Tehran, IR Iran. Tel: +98-2188964763, Fax: +98-218262072.

E-mail address: Khedmat.h@gmail.com

hepatitis," "steatohepatitis," "NASH," "non-alcoholic fatty liver." Only articles published in English language journals to 2010 were reviewed. We also used the bibliographies of relevant articles as well as their citations to enhance our search.

Epidemiology

It is estimated that about 8% of general population has elevated serum aminotransferase levels (12) and majority of them are NAFLD. The most important risk factors for NAFLD are male sex, age, obesity, insulin resistance and cardio-metabolic alterations that define the metabolic syndrome. The prevalence of NAFLD is 80%-90% in obese adults and up to 90% in patients with hyperlipidemia; the prevalence of NAFLD among children is 3%-10%, rising up to 40%-70% among obese children (13). Twenty percent of NAFLD patients are supposed to have necro-inflammation and degrees of pericellular fibrosis in their liver biopsy specimens and "NASH" is the term used to address this condition. Since definite diagnosis of NASH needs liver biopsy and histopathological studies, the exact prevalence of the disease has not yet been defined in the general population. But, studies on patients undergone liver biopsies for routine indications have demonstrated a prevalence of 1.2% in Japan (14) to approximately 7%-9% in western countries (4).

Demography

NASH generally occurs within the 5th and 6th decades of life (4, 15-18), although cases in earlier decades of life have also been reported (11, 12). NASH is also believed to occur more frequently in women (4, 5, 16, 19-22), although Bacon, *et al.*, (17) reported that a higher proportion of NASH patients were male (58%). There is nothing about the reason behind this gender disparity in NASH patients, although hormonal effects and a higher prevalence of obesity in women, may make NASH more prevalent in them (23). Female gender and younger age tend to have a relatively lower prevalence of hepatocellular carcinoma (HCC) due to NASH (11). Obesity is the condition most often associated with NASH: The first evidence showing an association between obesity and liver histopathological abnormalities including steatosis, inflammation, and fibrosis was achieved in 1958 (24). Different studies have reported that a high proportion of NASH patients are obese with a body weight >10% above the normal ranges. Obesity was also strongly associated with NASH (5, 16, 17, 25-27), although studies recommended obesity as a confounding variable which is more likely to exist concomitant with diabetes mellitus (28); in accordance with this conclusion, Bacon and colleagues (17) reported a low prevalence of obesity of 39%. Although weight reduction is one of the most proposed treatment strategies in obese people with NASH (29), surgical weight reduction has also been reported as an etiological factor associated with liver dysfunction (16). While, it is proposed that gradual weight reduction of about 0.5 to 1.6 kg per week to work as a curative method for NASH management, accelerated weight loss may worsen the clinical picture (30-32).

Diabetes mellitus

Non-insulin-dependent diabetes mellitus and elevated blood glucose values are noted in 21%-75% of patients with

NASH (4, 5, 20, 33, 34) and is one of the major risk factors of the disease (19, 35-40); although Baldrige and colleagues (41) found normal fasting blood sugar levels in all their pediatric patients with NASH. In an autopsy study, Wanless and Lentz (26) found a higher prevalence of NASH in patients with type II diabetes mellitus. Hyperlipidemia has been reported in 20%-92% of patients with NASH (15-17, 19, 27, 42). Elevated serum triglycerides and/or low serum high-density lipoprotein (HDL) cholesterol are found in up to 82% of patients with NASH and is also reported to be significantly associated with the disease (27, 43-45). Serum low-density lipoprotein (LDL) cholesterol and total cholesterol are less commonly reported to be associated with NASH. A recent study on mice (46), showed a prominent role of cholesterol during the development, inhibition and reversal of hepatic inflammation in NASH. Other conditions that are less commonly associated with NASH include total parenteral nutrition (47), jejunal diverticulosis with bacterial overgrowth (48), biliopancreatic diversion (49), Weber-Christian disease (50), partial lipodystrophy (51), abetalipoproteinemia (52), and therapy with certain drugs (53-56).

Pathogenesis and pathophysiology

It seems that NASH is multifactorial and its pathogenesis is not well defined. Since now, several factors have been proposed to cause or contribute to development of NASH (Table 1). Accumulation of triglyceride-filled vacuoles within the hepatocyte cytoplasm which leads to fatty liver is generally considered as a benign condition; however, NASH develops inevitably subsequent to fatty liver. This shows that fatty liver can result in consequences that lead to NASH. Pathogenesis of NASH is proposed to be based on a two-hit model (57-59). The first hit is hepatic steatosis that makes the liver susceptible to some hepatic insults leading to inflammation, steato-necrosis and fibrosis (60). Hepatic steatosis has been demonstrated to be associated with insulin resistance (27, 61-63). However, insulin resistance is shown to be a mechanism protecting tissues from fat accumulation which provokes through an increase in plasma free fatty acid and cytokine levels (64, 65). Free fatty acids activate an enzymatic cascade that impairs normal tyrosine phosphorylation of insulin receptor substrates, resulting in failure to transportation of glucose into the cell (22, 60, 65, 66). There are a number of factors that have been reported to contribute to interruptions in physiologic pathways in NASH patients: Diets consisting of excessive saturated fatty acids and cholesterol (63, 67, 68), a reduced ability of insulin to inhibit lipolysis (61), and decreased levels of proteins involving in VLDL metabolism (61, 69, 70). The second hit includes excessive amounts of oxidative stress and pro-inflammatory cytokines but reduction in hepatic ATP production. Accumulations of fat in the liver and augmented levels of free fatty acids are major players in the pathogenesis of NASH. High levels of fat within the liver can occur due to an increased free fatty acids absorption by the liver, decreased oxidation of them, excessive synthesis of them in the liver, and decreased production of VLDL cholesterol by the liver (71, 72). Metabolism of free fatty acids in the liver provokes reactive oxygen species (ROS) that produces free radicals. These highly reactive molecules induce a destructive metabolism for free fatty acids known as lipid peroxidation that results in cellular membrane disruption and cellular dysfunction (73). Intraperitoneal injec-

tion of insulin during long-term peritoneal dialysis results in steatohepatitis in the liver (74). This fact may suggest that insulin plays a role in NASH associated with obesity. Insulin reduces metabolism of free fatty acids, so as a result, levels of toxic free fatty acids in the liver raise up (75); moreover, obese patients are also resistant to insulin and have higher plasma levels of free fatty acids (76). Insulin levels in obese patients are sufficient to inhibit free fatty acids delivery by the liver, thus, elevated insulin levels leads to accumulation of free fatty acids in the liver. The pathogenesis of NASH following jejunal (including jejunocolic and jejunoleal) bypass surgery for weight reduction is complex and multifactorial. Mechanisms suggested to explain the pathogenesis include bacterial products absorbed from the blind loop as well as the bile acids (77-80), protein-energy malnutrition

(81), vitamins deficiency (78), and pathologic mobilization of free fatty acids during weight loss (82). For prevention of hepatic failure after jejunal bypass, a dietary regimen with low fat and carbohydrates but high in protein has been recommended (83). Intravenous carbohydrates have been shown to induce fatty liver in the critically ill patients (26). Fatty acids are synthesized within the liver when there is a need for, and enhances by high-carbohydrate and low-fat regimens. Hyperinsulinemia occurring due to carbohydrate overuse, insulin resistance and critical illness, is responsible for the elevated de novo fatty acid synthesis (84, 85). Another mechanism suggested for the pathogenesis of NASH is that lipolysis can mobilize free fatty acids from adipose tissue to liver (86). This mechanism of action is proposed in patients with decreased insulin action (as seen in hypoinsulinemia and

Table 1: Potential etiologies of NASH

1. Drugs or Toxins	
Metals	
Antimony	Carbon disulfide
Barium salts	Thallium compounds
Antibiotics	
Bleomycin	Tetracycline
Other drugs	
Amiodarone	Tetracycline
Coumadin	Valproic acid
Synthetic estrogens	Methotrexate
Glucocorticosteroids	Cocaine
Perhexilene maleate	Didanosine
Aspirin	Fialuridine
Calcium-channel blockers	Zidovudine
Tamoxifen	
2. Metabolic disorders	
Abetalipoproteinemia	Glycogen storage disease
Lipodystrophy	Weber-Christian syndrome
Dysbetalipoproteinemia	Wilson's disease
Hyperlipidemia	Wolman's disease
Galactosemia	
3. Nutritional	
Obesity	Total parenteral nutrition
Diabetes and hyperglycemia	Rapid weight loss
Intravenous glucose therapy in the week before death	Kwashiorkor
4. Surgical	
Jejuno colic bypass	Gastroplasty
Jejunoileal bypass	Extensive small bowel resection
Biliopancreatic diversion	
5. Other disorders	
Inflammatory bowel disease	Hepatotoxins: phosphorus,
Jejunal diverticulosis with bacterial overgrowth	Petrochemicals, organic solvents
Small bowel bacterial overgrowth	Acute starvation
Human immunodeficiency virus infection	

insulin resistance), rapid weight reduction or acute starvation, or exposed to high level of corticosteroids, leptin, and tumor necrosis factor alpha (TNF- α) (64, 87, 88). When obese people fast for a weight reduction, insulin levels decrease; however, insulin levels in obese patients who have had gastrointestinal bypass surgery for weight reduction augments since they continue to receive carbohydrates stimulating insulin secretion. Increased insulin levels in these patients result in the accumulation of free fatty acids in the liver, as mentioned above. Other proposed pathophysiological mechanisms for the development of NASH include attenuated mitochondrial beta oxidation causing increased forma-

tion of reactive oxygen species and ATP depletion (89). Three main mechanisms have been proposed for triggering steatohepatitis and fibrosis by mitochondria which are generally considered as the main sources of reactive oxygen species: lipid peroxidation, cytokine induction and induction of Fas ligand. Reactive oxygen species (ROS) cause lipid peroxidation, releases malon-dialdehyde (MDA) and μ -hydroxynoneal (HNE) and induces formation of cytokines TNF- α , TGF-beta and IL-8. Mitochondrial ROS cause expression of Fas ligand on hepatocytes, which may interact with Fas ligand of other hepatocytes causing death (90). MDA and HNE may further facilitate cell death and collagen synthesis. Moreover, con-

centration of free fatty acids in the hepatocytes may result in mitochondrial swelling, increased fragility, and membrane permeability that may lead to an increased ratio of mitochondrial AST to total AST in NASH patients.

Clinical Features

About 48%–100% of NASH patients are asymptomatic (5, 17, 91). Nonspecific constitutional symptoms including feeling of fullness, discomfort, or vague pain in the upper right abdominal quadrant (in about 25% of patients), profound prolonged lethargy (17, 92), weakness, fatigue and malaise (17) exist in a third of NASH patients (17). Pediatric NASH patients more frequently present with clinical symptoms other than those of adults (41, 92). Most patients have abnormal liver function tests incidentally found when performing laboratory tests for checkup or other conditions (such as hypertension, gallstones, coronary artery disease, congestive heart failure, cancer, peripheral vascular disease, hypothyroidism, and gynecologic or psychiatric conditions) (23). Although significant alcohol consumption is an exclusion criterion for the diagnosis of NASH, most patients report an alcohol intake of less than 20–40 g/day. However determining the amount of alcohol consumed by patients who gave history of alcohol consumption is difficult to verify, and even many patients who consume excessive amounts of alcohol underestimate or deny alcohol ingestion (93), due to memory mistakes, cultural issues as well as legal anxieties in certain countries like Iran. Pinto and colleagues (33) suggest that it is difficult to differentiate patients with NASH from alcoholic hepatitis based on clinical and biochemical evaluations alone. Baker, *et al* (94), suggested that alcohol may contribute to the development of NAFLD in human subjects. NASH has no direct physical signs that can directly lead the physician to diagnose the disease. The most common finding at the initial presentation is obesity which is present in up to 100% of NASH patients (95). Asymptomatic hepatomegaly, without evidence of chronic liver disease is the second most common physical sign of NASH that has been reported in up to 75% of patients when measured by palpation and percussion (16, 17); the rate is 90% by ultrasonographic evaluations (5). Splenomegaly is the third most commonly recognized sign of NASH reported in 6% to 25% (4) of patients. A recent study on 84 NAFLD patients (62 had NASH) (96), demonstrated that spleen body index (SBI) measured by computed tomography might be a non-invasive and simple method of differentiating NASH and simple steatosis particularly in the early stages of the disease. In this study, the SBI was significantly correlated with the discrimination of simple steatosis and NASH with mild fibrosis on multiple logistic regression analysis.

Laboratory evaluations

NASH patients typically present with mild to moderate elevations of serum aminotransferase levels, reported 1.5–4 times the upper limit of normal (22, 34, 42, 97, 98). Although serum aminotransferase levels are the most commonly used method for screening of NASH, these lack sufficient sensitivity to detect patients with NASH; these test cannot predict hepatic injury as well (99). Less than one-third of NASH patients present with elevated alkaline phosphatase. It has been demonstrated that alanine transaminase (ALT)

has positive correlations both with dyslipidemia and family history of liver disease (98). In up to 95% of patients with alcoholic liver disease, serum ALT level is higher than AST (17, 100–102). However, this is not a general rule and conflicting results have been reported (20). On the other hand, in those with severe NASH, the serum level of AST is higher than ALT. There was no significant difference between fibrotic and non-fibrotic disease in one study (102), though in another study, abnormal AST was associated with fibrotic NAFLD (103). AST can better differentiate simple steatosis and NASH than ALT in morbidly obese patients (103). A recent study by Puljiz, *et al* (104), on patients with elevated ALT showed that 30% had NASH and that high triglyceride, low HDL and high serum ferritin levels correspond with NASH. Although it is generally believed that, liver function indices such as prothrombin time (PT), albumin, total protein, and bilirubin, are almost always within the normal range (15, 17, 23, 40, 97, 105), there are exceptions possibly due to hepatic injury and malnutrition in which laboratory abnormalities including hypoalbuminemia, prolonged PT, and hyperbilirubinemia, may be found in patients with end-stage liver disease (57). Prothrombin activity level may also be able to predict fibrosis progression in NASH patients; it is reported that patients with progressive fibrosis have lower prothrombin activity than those with non-progressive fibrosis NASH (40). Hyperinsulinemia as well as an impaired glucose tolerance is a common finding in NASH patients. It is found in more than half of the patients; C-peptide levels are increased in 96% of patients, reflecting insulin hypersecretion (27). This is also suggested as a major factor in the pathogenesis of pediatric NASH (106). It is suggested that insulin resistance is the main predictor of NASH. Moreover, insulin level is higher in those with higher histological classes of NASH (20). On the other hand, hyperinsulinemia is frequently observed in the conditions with which NASH is highly associated, including visceral obesity, type 2 diabetes mellitus, high serum ferritin levels, and parenteral nutrition in critically ill patients (25, 26, 107–110). Hyperinsulinemia is also shown to be associated with the stage of fibrosis in hepatitis C virus infection (111). Although, as it is mentioned earlier, hyperinsulinemia elevates *de novo* fatty acid synthesis (82, 83)—a condition which is the main pathogenesis of NASH, we have no strict evidence showing whether hyperinsulinemia is an independent factor associated with NASH or it is only seen concurrent to these conditions. Dyslipidemias are also common abnormalities observed in NASH and have been reported in up to 81% of patients (4, 5, 15–17, 33, 112–114). Although Bacon, *et al*, (17) found no statistically significant difference between NASH patients and controls in terms of prevalence of dyslipidemia. It is suggested that hypertriglyceridemia is more likely to increase the risk of NAFLD than hypercholesterolemia (115). Evidence suggests that among different types of cholesterol, abnormality of HDL is the most frequent lipid profile abnormality in NASH patients, while LDL as well as total cholesterol are more likely to be within normal ranges (61, 103). However, data also exist reporting adverse results (114, 116). In one study (102), no significant difference was observed among different classes of the disease in terms of triglyceride and cholesterol levels. Those with moderate NASH had 1.5 and 2 times higher serum levels of serum triglyceride and cholesterol than those in patients with severe NASH, respectively. Imaging modalities as well as other noninvasive

methods are not accurate for the diagnosis of NASH. The presence of fat in the liver can be diagnosed by ultrasonography, computed tomography (CT), and magnetic resonance imaging (MRI). However, these techniques lack enough power to differentiate between fatty liver and NASH. At the moment, ultrasonography is the imaging technique of choice for evaluation of steatosis because it is relatively cheap, riskless, available, and yielding the best results (22). When patients present with elevated liver enzymes, ultrasound of the liver is frequently performed to detect steatosis. It manifests itself as a hyperechoic texture or a bright liver compared to kidney echogenicity (117), dark shadows posterior to the liver with vague intrahepatic vascular pattern; fibrosis can enhance echogenicity producing a coarse echo pattern showing well-defined portal veins (97, 118). Ultrasonography also has more sensitivity in detecting abnormalities in the total amount of hepatic fatty content, compared to CT (119). Despite all advantages of ultrasonography in detecting hepatic steatosis, it is not a specific method and cannot be used to diagnose NASH. When changes in fatty content are focal, CT and MRI are superior to ultrasonography. Several new techniques in MRI like fast gradient echo techniques (modified Dixon method) have resulted in substantial advances in the ability to diagnose a fatty liver by MRI (120).

Treatment

Since the pathogenesis as well as distinct molecular pathophysiological course of NASH have not yet been elucidated and for lack of properly designed large trials on NASH patients, there is no general consensus on the treatment strategy for NASH. However, based on prognosis of patients with NASH, need for effective therapies to prevent its progression seems evident.

Weight Management

Lifestyle modifications should include nutritional interventions as well as exercise implementation (121). Protein-energy imbalance such as excessive energy intake has been shown to be consistently associated with higher prevalence of hepatic steatosis (122). In obese patients, moderate weight loss of about 6% via caloric restriction has been shown to result in improvements in intrahepatic lipid content (123). Another study showed that weight loss through caloric restrictions results in improvement in steatosis in serial liver histological evaluations (124). It also has been shown that weight reduction can normalize serum aminotransferase activities in overweight people who present with aminotransferase abnormalities both in children and adults (125, 126). Clinical trials have also demonstrated a substantial reduction in aminotransferase levels in patients with NAFLD when they are put on calorie-restricted diets whether or not on an exercise program (2, 125-131). On the other hand, it has been shown that the degree of improvement in insulin sensitivity is related to the exercise intensity possibly due to its role in increasing the oxidative capacity and utilization of fatty acids by muscles (132). Moreover, it is known that type of diet and rates of weight loss are important components in the efficacy of the treatment. For example, insulin resistance can be improved by a fiber-rich diet but not by diets consisting of high levels of saturated fats (133). Furthermore, a very rapid weight loss may increase portal

inflammation and fibrosis; it is recommended that weight reduction should not exceed 1.6 kg per week (32). A reasonable diet in adults also has been suggested to contain 45-100 g high quality animal protein, less than 100 g carbohydrates (avoiding high fructose value regimens) (134) and less than 10 g fat (with decreased intake of saturated and trans lipids) (135) per day comprising around 600 to 800 kcal of energy (28). Through this approach, it is highly recommended that gradual weight loss should be performed through the combination of dietary restrictions along with regular aerobic exercise regimen of at least 30-45 minutes three to seven times a week. A recent article by Centis, *et al* (136), suggest that cognitive-behavior treatment would also be a good approach and should be considered for patients with NAFLD. This treatment can be coupled with prevention strategies at the population level.

Pharmacologic intervention

A number of studies have investigated the usefulness of medications for weight reduction. Since now, a number of drugs are in phase III trials to get approval for treatment of NASH. The drugs include orlistat, metformin, vitamin E, rosiglitazone, and pioglitazone (63, 137). Orlistat, a reversible inhibitor of gastric and pancreatic lipase, has been proven in weight reduction; however, its value in the treatment of NASH needs more evaluations. A clinical trial showed that orlistat can achieve a body weight reduction of over 10 kg as well as significant reductions in serum transaminase levels in obese patients with NASH (138, 139); but side effects of this drug including diarrhea and bloating has made it less attractive. On the other hand, in a more recent study, Harrison, *et al*, showed that orlistat has no superiority in terms of weight loss or histological improvement to calorie restriction alone (140). Rimonabant, a selective antagonist for endocannabinoid receptor 1, is approved for weight reduction. In addition, it is proposed that this agent may have some favorable anti-steatotic and anti-fibrotic values (141-144). Ursodeoxycholic acid (UDCA), a cytoprotective agent, has been demonstrated to be useful and safe in patients with chronic liver diseases such as primary biliary cirrhosis and primary sclerosing cholangitis (145). In NASH, it caused significant decreases in the levels of liver enzymes and normalization in 77%-87% of patients (146-149). After one year after drug use, it has also improved steatosis at ultrasonogram (149) and histological grade (146) but it had no effect on fibrosis (149). On the other hand, a randomized trial on NAFLD patients showed no advantage by using UDCA over placebo when added to a hypocaloric diet (150). A review of four randomized controlled trials showed no significant difference regarding mortality or improvement in liver function tests after treatment with UDCA (151). In an open-label pilot study, Laurin, *et al*, (146) tested the effect of UDCA against clofibrate on NAFLD patients. They found that significant improvements have been achieved in serum hepatic enzymes (alkaline phosphatase, aminotransferases, gamma-GT) as well as grade of steatosis at liver biopsy. Kiyici, *et al*, (149) also confirmed results of the said study against atorvastatin. However, two other studies found no advantages for UDCA on hepatic enzyme abnormalities and NASH (152, 153). Lindor, *et al*, also suggest that there is a possibility for a spontaneous improvement in liver enzymes in patients with NAFLD associated with improvements in the degree of steatosis and fibrosis. In another

study by Obinata, *et al*, (154) taurine, an agent in the same drug category, was found to improve aminotransferase levels regardless of weight changes in children with NASH.

Metformin

Several studies have consistently showed association between insulin resistance and elevated aminotransferase levels in NASH (155, 156). This forms a basis for the use of insulin sensitizers with the presumption that it could improve NAFLDs. Metformin, a biguanide, reduces hyperinsulinemia and has therapeutic advantages as an anti-diabetic agent and insulin sensitizer. Its anti-diabetic action is through diminishing glucose absorption in the intestinal tract, down-regulating hepatic gluconeogenesis, and facilitating glucose uptake and utilization by diverting fatty acids from lipid production to mitochondrial oxidation (157, 158). It also has stimulatory effects on AMP-activated protein kinase and modulation of hepatic TNF- α expression (159, 160). In an open label controlled study, Marchesini, *et al* (105), found that metformin significantly reduces liver volume, moderately improves insulin sensitivity, and normalizes aminotransferase levels in 50% of cases; medication withdrawal led to a return of aminotransferase levels to pre-treatment values. It also has been shown that its beneficial effect on serum aminotransferase normalization is greater than that can be achieved through dietary modification alone (161). It has already been shown that treatment with metformin improved inflammation and hepatic steatosis in steatotic animal models (160). However, there are few small controlled studies in which effect of metformin on hepatic histology in patients with NASH is examined. For example, a randomized study on 36 patients with NASH treated with dietary counseling with or without metformin confirmed the preliminary knowledge of improved serum aminotransferases and insulin sensitivity by metformin but failed to show a significant improvement in necro-inflammation and fibrosis on repeated liver biopsy (162). The same results were achieved when metformin was examined against rosiglitazone (163); on the other hand, in an open-label randomized study, repeated liver biopsies in 17 patients with NASH who received metformin demonstrated significant improvement in steatosis, necroinflammation, and fibrosis (164). We therefore, recommend use of metformin in patients with NASH, since most patients with NASH including non-diabetics have glucose intolerance and the least advantage of using metformin is a decrease in the risk of developing diabetes in these patients (165). Loomba, *et al*, also confirmed beneficial effects of metformin in the treatment of NASH (166). Schwimmer, *et al*, also found the same results in a pediatric group with NASH (167).

Thiazolidinediones (Glitazones) improve insulin sensitivity in adipose tissue by activating the nuclear transcription factor on peroxisome proliferators-activated receptor gamma (PPAR-gamma) (168). The first evidence on a potential beneficial effect of thiazolidinediones use in NASH patients was achieved by Caldwell, *et al* (169, 170), in which 7 out of 10 patients receiving troglitazone normalized aminotransferase levels—although no significant histological response was attained. This agent has been withdrawn from the market due to its hepatotoxicity (171). In a study by Promrat, *et al*, (172) 72% of patients who received pioglitazone for almost a year experienced normalization of serum ALT, steatosis, necro-inflammation, and fibrosis on liver histology. Radio-

logical evaluations by MRI showed significant decreases in liver volume and fat content. In another study, pioglitazone at a dose of 15 mg/day for three months normalized ALT levels in all the 12 patients with NASH (173). A more recent randomized clinical trial by Belfort, *et al*, showed biochemical and histological improvements associated with the use of pioglitazone (174). Similar results have been achieved through other studies on pioglitazone (175-177). Oruc, *et al*, demonstrated that rosiglitazone 4 mg/day for three months improves aminotransferases and insulin sensitivity in fatty liver diseases (178). Another large study employing rosiglitazone revealed the same results plus histological improvements in patients with NASH (179). The only adverse effects associated with thiazolidinediones are mild weight gain and rare hepatotoxicity (180, 181). Moreover, rosiglitazone is suggested to rarely cause silent cardiac failure which is more likely to occur in conditions most prevalently existing in patients with NASH (hypertension and metabolic syndrome) (182). On the other hand, discontinuation of pioglitazone is shown associated with a reversal of its beneficial effects on both biochemical markers as well as histological findings (183).

Lipid-lowering agents

Since dyslipidemia is a strong factor associated with NAFLD, attempts have been made to ameliorate lipid homeostasis and hypertriglyceridemia as a possible treatment for NASH. Although clofibrate is considered one of the main medications used for hypertriglyceridemia and reduces hepatic triglyceride in experimental models of hepatic steatosis, in human models, Laurin, *et al* (146), found no significant improvements in either enzyme levels or liver histology when the agent was used at a dose of 2 g/day for one year. However, in a controlled study, Basaranoglu, *et al* (184), found that gemfibrozil, another drug in the same drug category as clofibrate, was significantly effective in reducing aminotransferase levels in 74% of patients after four weeks of administration. In a report of two cases with NASH under treatment with tamoxifen (185), bezafibrate prevented the histological damage progression of NASH. To our knowledge, these are the only published data existing in the literature on potential effects of clofibrate, bezafibrate, and gemfibrozil in NASH patients. Therefore, future studies with larger NASH population as well as more perfect methodologies (double blind randomized controlled trials) seems necessary. Statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, have also suggested as safe and having healing effects in patients with underlying liver diseases and serious hepatotoxicity is quite rare. The effect is almost universally reversible upon prompt discontinuation of the drug (186-189). Kiyici, *et al*, reported significant improvements in cholesterol and liver enzyme levels with atorvastatin when administered at a dosage of 10 mg/day for six months in patients with NASH and hyperlipidemia (149). However, fibrosis and necroinflammation were not improved compared to patients receiving UDCA. Another study on humans comparing the effects of atorvastatin with omega-3 fatty acids and orlistatin in patients with NAFLD (190), showed that orlistatin causes a greater improvement in histological indices while omega-3 fatty acids are more effective in reducing AST and triglyceride levels. Atorvastatin was also effective in reducing serum transaminase levels as well as ultrasonographic manifestations of NAFLD in patients presenting with hyper-

cholesterolemia. In another study, atorvastatin use was associated with improved serum aminotransferase levels and lipid levels in patients with NAFLD (191). As well, pravastatin at 20 mg/day for six months improved both liver enzymes and histological findings in patients with NASH (192). A recent study on 11 patients showed that long-term consumption of olive oil enriched with n-3 PUFA in patients with NAFLD is able to decrease circulating liver enzymes and triglycerides, with a significant improvement of adiponectin levels (193). Georgescu, *et al*, found that atorvastatin and losartan are efficient in the treatment of dyslipidemia- and hypertension-associated NASH, by improving both biochemical parameters and steatosis (194). They found similar efficacy for pentoxifylline in non-hypertensive/non-dyslipidemic patients, while UDCA did not improve the histological score, although it improved the biochemical parameters.

Antioxidants

At this time, there is a shortage of data supporting the use of vitamin E, as a potent therapeutic approach in NASH patients. Antioxidants first became candidate as potential therapeutic agents for NASH because oxidative stress is a well-known relevant factor in the pathogenesis of NASH (195). Moreover, serum levels of antioxidants such as vitamin E, have been shown to be low in obese children (196, 197). Lavine, demonstrated that supplementation with vitamin E results in normalization of ALT in children aged less than 16 years (198). Another one-year study on patients with NASH receiving vitamin E as well as dietary advice showed substantial improvement in histological findings of liver biopsy specimen (199). In a double-blind randomized study, 45 patient received vitamin E, vitamin C or placebo together with dietary counseling. Histological evaluations showed significant improvements in fibrosis score, although there were no changes in serum aminotransferase levels or inflammation (200). Kugelmas, *et al* (201), found no beneficial effect of vitamin E on serum cytokine levels. Silybin, a formulation of vitamin E showed biochemical improvement in patients with NASH but histological follow-up was not addressed in this study (202). On the other hand, Bugianesi, *et al*, in their open label randomized study, found that vitamin E has similar efficacy to prescriptive diet but inferior to metformin when looking at improvement in serum aminotransferase levels (164). Although, histological improvement was achieved by metformin, for lack of follow-up for vitamin E group, no data was achieved. Another randomized study showed that pioglitazone and vitamin E were more potent in improving steatosis and histological features of NASH than vitamin E alone (203). Vitamin E at a dosage of 300 mg/day for one year resulted in a significant reduction in AST, ALT, and g-GT and improvement in steatosis, inflammation, and fibrosis in liver biopsy of 12 patients with NASH (198). In another pilot study, vitamin E was administered for six months. After this time, liver enzymes, cholesterol, ultrasonographic and histological grade of steatosis, and inflammation were substantially improved (198). N-acetylcystein, a well-known antioxidant, was administered to 11 patients with NASH at a dosage of 1 g/day which resulted in significant decreases in serum aminotransferase levels after three months of therapy (204). Similar study employing N-acetylcysteine for one month demonstrated biochemical improvement in patients with NASH (205). Betaine is a component of the metabolic

cycle of methionine, capable of increasing S-adenosylmethionine levels and, as a result, decreasing the rate of hepatic steatosis. A 12-month treatment was associated with a significant improvement in ALT, AST, and histological grade of steatosis, inflammation, and fibrosis (206). When administered concomitantly with diethanolamine glucuronate and nicotinamide ascorbate in NASH patients for eight weeks, betaine caused a 10% improvement in aminotransferase levels as well as a 25% improvement in hepatic steatosis in a randomized controlled trial (207, 208). A review of six trials (209) showed that treatment with antioxidant supplements causes a statistical significant though not clinically important, amelioration of AST levels. However, ALT levels had no change. Moreover, gamma-glutamyl-transpeptidase was decreased, albeit not significantly in the treatment arm.

Other drugs

A recent study by Yoneda, *et al* (210), demonstrated improvements in the clinical parameters as well as histological observations by treatment with ezetimibe in 10 patients with NASH. Probiotics (211), anti-tumor necrosis factor alpha antibodies (212), pentoxifylline (213), and probucol (214). Treatment with silymarin has also been shown to have significant beneficial effects on biochemical factors in patients with NAFLD (215, 216).

Phlebotomy

Since association between NASH and elevated serum ferritin, transferrin and iron concentration or transferrin saturation is a proven fact (217), and that increased hepatic iron and excessive fat accumulation may interact to generate hepatic inflammation causing liver injury (164), one may consider phlebotomy as a potential procedure likely to reduce the inflammatory process. Facchini, *et al*, showed that severe iron depletion by phlebotomy, causes reduced glucose tolerance as well as a significant improvement in aminotransferase and glucose levels (218).

Advice regarding bariatric surgery

Since bariatric surgery is a known procedure that is associated with substantial improvement in metabolic syndrome (219), scientists considered this treatment as a potential therapy for overweight patients with NASH. Dixon, *et al*, demonstrated positive effects of gastric banding on steatosis, necro-inflammatory activity and fibrosis in 22 obese patients with NASH undergoing liver biopsies after a mean losing weight of 34 kg about two years after bariatric surgery (220). These beneficial effects were more pronounced in patients with metabolic syndrome. The studied population experienced a high remission rate of 82%. Similar results have not been observed in those who had undergone gastric bypass. Another study by Luyckx, *et al*, on patients undergoing gastric bypass also showed elevated inflammatory activities in liver biopsies of patients who achieved a faster weight loss than in those who lost weight by gastric banding (221). On the other hand, Klein, *et al*, showed significant improvement in metabolic parameters and hepatic expression of factors involved in liver inflammation in seven patients one year after Roux-en-Y gastric bypass (222). A larger study by Bakker, *et al*, showed significant improvements in steatosis, lobular

inflammation, and lobular and portal fibrosis in 19 morbidly obese patients with NASH who lost a mean of 52 kg of body weight, and repeated liver biopsies after almost two years post-Roux-en-Y gastric bypass(223). Dixon also reported beneficial effects for Roux-en-Y gastric bypass for patients with NASH(224). Furuva, *et al*, evaluated liver biopsies two years after gastric bypass in 18 patients with NAFLD and showed substantial improvements in all histopathologic findings of steatohepatitis(225). Jejunioleal bypass has also been proposed as a beneficial procedure for patients with NASH (82, 226). A study on 104 patients underwent second liver biopsy also showed significant improvement in fibrosis and inflammation after biliopancreatic diversion (158). A recent study on 116 patients who underwent laparoscopic bariatric surgery, including Roux-en-Y gastric bypass, adjustable gastric banding and biliopancreatic diversion with duodenal switch (227), revealed complete regression of NAFLD in 83% of patients; most of the remaining patients presented with mild NAFLD. Complete regression of necroinflammatory activity was observed in 93% of patients. Among the 12 patients presenting with fibrosis in the first biopsy, complete remission was observed in 10 and improvement in two. Two patients continued to show the same degree of fibrosis without evidence of disease activity. None of the patients had worsening of steatosis, necroinflammatory activity or fibrosis; none progressed to cirrhosis. A recent review of 25 cohort studies evaluating effects of bariatric surgery in patients with NASH (228) showed that in 21 studies, patients experienced improvement in steatosis or inflammation scores; four studies described some deterioration in the degree of fibrosis.

References

- Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. *Clin Gastroenterol Hepatol*. 2004;**2**(12):1048-58.
- Kadayifci A, Merriman RB, Bass NM. Medical treatment of non-alcoholic steatohepatitis. *Clin Liver Dis*. 2007;**11**(1):19-40, ix.
- Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. *Hepatology*. 2005;**41**(6):1313-21.
- Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. *Mayo Clin Proc*. 1980;**55**(7):434-8.
- Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. *Hepatology*. 1990;**11**(1):74-80.
- Jansen P. Non-alcoholic steatohepatitis. *Eur J Gastroenterol Hepatol*. 2004;**16**(11):1079.
- Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. *Gastroenterology*. 2002;**123**(1):134-40.
- Browning JD, Kumar KS, Saboorian MH, Thiele DL. Ethnic differences in the prevalence of cryptogenic cirrhosis. *Am J Gastroenterol*. 2004;**99**(2):292-8.
- Ratzliff V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-Tainturier MH, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. *Hepatology*. 2002;**35**(6):1485-93.
- Hui JM, Kench JG, Chitturi S, Sud A, Farrell GC, Byth K, et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. *Hepatology*. 2003;**38**(2):420-7.
- Shimada M, Hashimoto E, Tani M, Hasegawa K, Okuda H, Hayashi N, et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. *J Hepatol*. 2002;**37**(1):154-60.
- Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. *Am J Gastroenterol*. 2003;**98**(5):960-7.
- Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. *Dig Dis*. 2010;**28**(1):155-61.
- Propst A, Propst T, Judmaier G, Vogel W. Prognosis in nonalcoholic steatohepatitis. *Gastroenterology*. 1995;**108**(5):1607.
- Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. *Hum Pathol*. 1989;**20**(6):594-8.
- Itoh S, Yougel T, Kawagoe K. Comparison between nonalcoholic steatohepatitis and alcoholic hepatitis. *Am J Gastroenterol*. 1987;**82**(7):650-4.
- Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. *Gastroenterology*. 1994;**107**(4):1103-9.
- Park KS, Lee YS, Park HW, Seo SH, Jang BG, Hwang JY, et al. Factors associated or related to with pathological severity of nonalcoholic fatty liver disease. *Korean J Intern Med*. 2004;**19**(1):19-26.
- Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. *Hepatology*. 1999;**30**(6):1356-62.
- Boza C, Riquelme A, Ibanez L, Duarte I, Norero E, Viviani P, et al. Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass. *Obes Surg*. 2005;**15**(8):1148-53.
- Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. *Gastroenterology*. 1999;**116**(6):1413-9.
- Te Slight K, Bourass I, Sels JP, Driessen A, Stockbrugger RW, Koek GH. Non-alcoholic steatohepatitis: review of a growing medical problem. *Eur J Intern Med*. 2004;**15**(1):10-21.
- Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. *Ann Intern Med*. 1997;**126**(2):137-45.
- Zelman S. The liver in obesity. *AMA Arch Intern Med*. 1952;**90**(2):141-56.
- Felig P, Marliss E, Cahill GF, Jr. Plasma amino acid levels and insulin secretion in obesity. *N Engl J Med*. 1969;**281**(15):811-6.
- Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. *Hepatology*. 1990;**12**(5):1106-10.
- Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. *Hepatology*. 2002;**35**(2):373-9.
- Das K, Kar P. Non-alcoholic steatohepatitis. *J Assoc Physicians India*. 2005;**53**:195-9.
- Blackburn G. Very-Low-Calorie Diets for the Treatment of Obesity. *Obesity: pathophysiology, psychology, and treatment*. 1994.P197.
- Youssef WI, McCullough AJ. Steatohepatitis in obese individuals. *Best Pract Res Clin Gastroenterol*. 2002;**16**(5):733-47.
- Patrick L. Nonalcoholic fatty liver disease: relationship to insulin sensitivity and oxidative stress. Treatment approaches using vitamin E, magnesium, and betaine. *Altern Med Rev*. 2002;**7**(4):276-91.
- Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. *J Hepatol*. 1991;**12**(2):224-9.
- Pinto HC, Baptista A, Camilo ME, Valente A, Saragoca A, de Moura MC. Nonalcoholic steatohepatitis. Clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients. *Dig Dis Sci*. 1996;**41**(1):172-9.
- Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. *Hepatology*. 2003;**37**(5):1202-19.
- Lonardo A, Lombardini S, Ricchi M, Scaglioni F, Loria P. Review article: hepatic steatosis and insulin resistance. *Aliment Pharmacol Ther*. 2005;**22** (Suppl 2):64-70.
- Machado M, Cortez-Pinto H. Non-alcoholic steatohepatitis and metabolic syndrome. *Curr Opin Clin Nutr Metab Care*. 2006;**9**(5):637-42.
- Abrams GA, Kunde SS, Lazenby AJ, Clements RH. Portal fibrosis and hepatic steatosis in morbidly obese subjects: A spectrum of nonalcoholic fatty liver disease. *Hepatology*. 2004;**40**(2):475-83.
- Beymer C, Kowdley KV, Larson A, Edmonson P, Dellinger EP, Flum DR. Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery. *Arch Surg*. 2003;**138**(11):1240-4.
- Charlton M, Kasparova P, Weston S, Lindor K, Maor-Kendler Y, Wiesner RH, et al. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. *Liver Transpl*. 2001;**7**(7):608-14.
- Fassio E, Alvarez E, Dominguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. *Hepatology*. 2004;**40**(4):820-6.
- Baldrige AD, Perez-Atayde AR, Graeme-Cook F, Higgins L, Lavine JE. Idiopathic steatohepatitis in childhood: a multicenter retrospective study. *J Pediatr*. 1995;**127**(5):700-4.
- Reid AE. Nonalcoholic steatohepatitis. *Gastroenterology*. 2001;**121**(3):710-23.
- Laurin J. Motion - all patients with NASH need to have a liver biopsy: arguments against the motion. *Can J Gastroenterol*. 2002;**16**(10):722-6.

44. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. *Diabetes*. 2001;**50**(8):1844-50.
45. Musso G, Gambino R, De Michieli F, Cassader M, Rizzetto M, Durazzo M, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. *Hepatology*. 2003;**37**(4):909-16.
46. Wouters K, van Bilsen M, van Gorp PJ, Bieghs V, Lutjohann D, Kerksiek A, et al. Intrahepatic cholesterol influences progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice. *FEBS Lett*. 2010;**584**(5):1001-5.
47. Clain DJ, Lefkowitz JH. Fatty liver disease in morbid obesity. *Gastroenterol Clin North Am*. 1987;**16**(2):239-52.
48. Nazim M, Stamp G, Hodgson HJ. Non-alcoholic steatohepatitis associated with small intestinal diverticulosis and bacterial overgrowth. *Hepato-gastroenterology*. 1989;**36**(5):349-51.
49. Grimm IS, Schindler W, Haluszka O. Steatohepatitis and fatal hepatic failure after biliopancreatic diversion. *Am J Gastroenterol*. 1992;**87**(6):775-9.
50. Kimura H, Kako M, Yo K, Oda T. Alcoholic hyalins (Mallory bodies) in a case of Weber-Christian disease: electron microscopic observations of liver involvement. *Gastroenterology*. 1980;**78**(4):807-12.
51. Powell EE, Searle J, Mortimer R. Steatohepatitis associated with limb lipodystrophy. *Gastroenterology*. 1989;**97**(4):1022-4.
52. Partin JS, Partin JC, Schubert WK, McAdams AJ. Liver ultrastructure in abetalipoproteinemia: Evolution of micronodular cirrhosis. *Gastroenterology*. 1974;**67**(1):107-18.
53. Itoh S, Igarashi M, Tsukada Y, Ichinoe A. Nonalcoholic fatty liver with alcoholic hyalin after long-term glucocorticoid therapy. *Acta Hepatogastroenterol (Stuttg)*. 1977;**24**(6):415-8.
54. Poucell S, Ireton J, Valencia-Mayoral P, Downar E, Larratt L, Patterson J, et al. Amiodarone-associated phospholipidosis and fibrosis of the liver. Light, immunohistochemical, and electron microscopic studies. *Gastroenterology*. 1984;**86**(5 Pt 1):926-36.
55. Pratt DS, Knox TA, Erban J. Tamoxifen-induced steatohepatitis. *Ann Intern Med*. 1995;**123**(3):236.
56. Seki K, Minami Y, Nishikawa M, Kawata S, Miyoshi S, Imai Y, et al. "Nonalcoholic steatohepatitis" induced by massive doses of synthetic estrogen. *Gastroenterol Jpn*. 1983;**18**(3):197-203.
57. Angulo P. Nonalcoholic fatty liver disease. *N Engl J Med*. 2002;**346**(16):1221-31.
58. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. *Semin Liver Dis*. 2001;**21**(1):27-41.
59. Day CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? *Gut*. 2002;**50**(5):585-8.
60. Day C. Pathogenesis of steatohepatitis. Best practice and research. *Clin Gastroenterol*. 2002;**16**(7):663.
61. Marchesini G, Forlani G. NASH: from liver diseases to metabolic disorders and back to clinical hepatology. *Hepatology*. 2002;**35**(2):497-9.
62. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. *Hepatology*. 2002;**35**(2):367-72.
63. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. *Gastroenterology*. 2001;**120**(5):1183-92.
64. Haque M, Sanyal AJ. The metabolic abnormalities associated with non-alcoholic fatty liver disease. *Best Pract Res Clin Gastroenterol*. 2002;**16**(5):709-31.
65. Shulman GI. Cellular mechanisms of insulin resistance. *JCI*. 2000;**106**(2):171-6.
66. Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. *Hepatology*. 2003;**37**(2):343-50.
67. de Almeida IT, Cortez-Pinto H, Fidalgo G, Rodrigues D, Camilo ME. Plasma total and free fatty acids composition in human non-alcoholic steatohepatitis. *Clin Nutr*. 2002;**21**(3):219-23.
68. Cassader M, Gambino R, Musso G, Depetris N, Mecca F, Cavallo-Perin P, et al. Postprandial triglyceride-rich lipoprotein metabolism and insulin sensitivity in nonalcoholic steatohepatitis patients. *Lipids*. 2001;**36**(10):1117-24.
69. Bernard S, Touzet S, Personne I, Lapras V, Bondon PJ, Berthezene F, et al. Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with type II diabetes. *Diabetologia*. 2000;**43**(8):995-9.
70. Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair KS. Apolipoprotein synthesis in nonalcoholic steatohepatitis. *Hepatology*. 2002;**35**(4):898-904.
71. Dianzani M. Biochemical aspects of fatty liver. *Hepatotoxicology*. 1991:327-99.
72. Lombardi B. Considerations on the pathogenesis of fatty liver. *Lab Invest*. 1966;**15**(1 Pt 1):1-20.
73. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. *Hepatology*. 2003;**37**(6):1286-92.
74. Wanless IR, Bargman JM, Oreopoulos DG, Vas SI. Subcapsular steatonecrosis in response to peritoneal insulin delivery: a clue to the pathogenesis of steatonecrosis in obesity. *Mod Pathol*. 1989;**2**(2):69-74.
75. McGarry JD, Foster DW. Regulation of hepatic fatty acid oxidation and ketone body production. *Annu Rev Biochem*. 1980;**49**:395-420.
76. Bogardus C, Lillioja S, Howard BV, Reaven G, Mott D. Relationships between insulin secretion, insulin action, and fasting plasma glucose concentration in nondiabetic and noninsulin-dependent diabetic subjects. *J Clin Invest*. 1984;**74**(4):1238-46.
77. Carey JB, Jr., Wilson ID, Zaki FG, Hanson RE. The metabolism of bile acids with special reference to liver injury. *Medicine (Baltimore)*. 1966;**45**(6):461-70.
78. Drenick EJ, Simmons F, Murphy JF. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small-bowel bypass. *N Engl J Med*. 1970;**282**(15):829-34.
79. McGill DB, Humpherys SR, Baggenstoss AH, Dickson ER. Cirrhosis and death after jejunioleal shunt. *Gastroenterology*. 1972;**63**(5):872-7.
80. Sherr HP, Nair PP, White JJ, Banwell JG, Lockwood DH. Bile acid metabolism and hepatic disease following small bowel bypass for obesity. *Am J Clin Nutr*. 1974;**27**(12):1369-79.
81. Moxley RJ, 3rd, Pozefsky T, Lockwood DH. Protein nutrition and liver disease after jejunioleal bypass for morbid obesity. *N Engl J Med*. 1974;**290**(17):921-6.
82. Marubbi AT, Jr., Buchwald H, Schwartz MZ, Varco R. Hepatic lesions of central pericellular fibrosis in morbid obesity, and after jejunioleal bypass. *Am J Clin Pathol*. 1976;**66**(4):684-91.
83. Baddeley RM. An epilogue to jejunioleal bypass. *World J Surg*. 1985;**9**(6):842-9.
84. Schwarz JM, Linfoot P, Dare D, Aghajanian K. Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. *Am J Clin Nutr*. 2003;**77**(1):43-50.
85. Parks EJ. Dietary carbohydrate's effects on lipogenesis and the relationship of lipogenesis to blood insulin and glucose concentrations. *Br J Nutr*. 2002;**87**(Suppl 2):S247-53.
86. Carlson L, Boberg J, Hogstedt B. Some physiological and clinical implications of lipid mobilization from adipose tissue. *Handbook of physiology*. 1965;**5**:625-44.
87. Fruhbeck G, Gomez-Ambrosi J, Muruzabal FJ, Burrell MA. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. *Am J Physiol Endocrinol Metab*. 2001;**280**(6):E827-47.
88. Van Steenberghe W. Niet-alcoholische steatohepatitis: een oorzaak van levercirrose bij obesitas en diabetes mellitus. *Tijdschrift voor Geneeskunde*. 1999;**55**:1419-24.
89. Berson A, De Bevo V, Letteron P, Robin MA, Moreau C, El Kahwaji J, et al. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. *Gastroenterology*. 1998;**114**(4):764-74.
90. Levey CM. Fatty liver: a study of 270 patients with biopsy proven fatty liver and review of the literature. *Medicine (Baltimore)*. 1962;**41**:249-76.
91. Diehl AM, Goodman Z, Ishak KG. Alcohol-like liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. *Gastroenterology*. 1988;**95**(4):1056-62.
92. Moran JR, Ghishan FK, Halter SA, Greene HL. Steatohepatitis in obese children: a cause of chronic liver dysfunction. *Am J Gastroenterol*. 1983;**78**(6):374-7.
93. Lumeng L. New diagnostic markers of alcohol abuse. *Hepatology*. 1986;**6**(4):742-5.
94. Baker SS, Baker RD, Liu W, Nowak NJ, Zhu L. Role of alcohol metabolism in non-alcoholic steatohepatitis. *PLoS One*. 2010;**5**(3):e9570.
95. Ariz U, Mato JM, Lu SC, Martinez Chantar ML. Nonalcoholic steatohepatitis, animal models, and biomarkers: what is new? *Methods Mol Biol*. 2010;**593**:109-36.
96. Suzuki K, Kirikoshi H, Yoneda M, Mawatari H, Fujita K, Nozaki Y, et al. Measurement of spleen volume is useful for distinguishing between simple steatosis and early-stage non-alcoholic steatohepatitis. *Hepatol Res*. 2010;**40**(7):693-700.
97. Knegt R. Non-alcoholic steatohepatitis: clinical significance and pathogenesis. *Scandinavian J Gastroenterol*. 2001;**36**(234):88-92.
98. Khedmat H, Fallahian F, Abolghasemi H, Hajibeigi B, Attarchi Z, Alaeddini F, et al. Serum gamma-glutamyltransferase, alanine aminotransferase, and aspartate aminotransferase activity in Iranian healthy blood donor men. *World J Gastroenterol*. 2007;**13**(6):889-94.
99. Adler M, Schaffner F. Fatty liver hepatitis and cirrhosis in obese patients. *Am J Med*. 1979;**67**(5):811-6.
100. Harnois F, Msika S, Sabate JM, Mechler C, Jouet P, Barge J, et al. Prevalence and predictive factors of non-alcoholic steatohepatitis (NASH)

- in morbidly obese patients undergoing bariatric surgery. *Obes Surg*. 2006;**16**(2):183-8.
101. Mehta K, Van Thiel DH, Shah N, Mobarhan S. Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants. *Nutr Rev*. 2002;**60**(9):289-93.
 102. Gupte P, Amarapurkar D, Agal S, Baijal R, Kulshrestha P, Pramanik S, et al. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. *J Gastroenterol Hepatol*. 2004;**19**(8):854-8.
 103. Ong JP, Elariny H, Collantes R, Younoszai A, Chandhoke V, Reines HD, et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. *Obes Surg*. 2005;**15**(3):310-5.
 104. Puljiz Z, Stimac D, Kovac D, Puljiz M, Bratanic A, Kovacic V, et al. Predictors of nonalcoholic steatohepatitis in patients with elevated alanine aminotransferase activity. *Coll Antropol*. 2010;**34** (Suppl 1):33-7.
 105. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. *Lancet*. 2001;**358**(9285):893-4.
 106. Roberts EA. Nonalcoholic steatohepatitis in children. *Curr Gastroenterol Rep*. 2003;**5**(3):253-9.
 107. Kerstetter J, Caballero B, O'Brien K, Wurtman R, Allen L. Mineral homeostasis in obesity: effects of euglycemic hyperinsulinemia. *Metabolism*. 1991;**40**(7):707-13.
 108. Caballero B, Wurtman RJ. Differential effects of insulin resistance on leucine and glucose kinetics in obesity. *Metabolism*. 1991;**40**(1):51-8.
 109. Bowyer BA, Fleming CR, Ludwig J, Petz J, McGill DB. Does long-term home parenteral nutrition in adult patients cause chronic liver disease? *JPEN J Parenter Enteral Nutr*. 1985;**9**(1):11-7.
 110. Peiris AN, Mueller RA, Smith GA, Struve MF, Kissebah AH. Splanchnic insulin metabolism in obesity. Influence of body fat distribution. *J Clin Invest*. 1986;**78**(6):1648-57.
 111. Mohammad Alizadeh AH, Fallahian F, Alavian SM, Ranjbar M, Hedayati M, Rahimi F, et al. Insulin resistance in chronic hepatitis B and C. *Indian J Gastroenterol*. 2006;**25**(6):286-9.
 112. Diehl AM. Nonalcoholic steatohepatitis. *Semin Liver Dis*. 1999;**19**(2):221-9.
 113. Crespo J, Cayon A, Fernandez-Gil P, Hernandez-Guerra M, Mayorga M, Dominguez-Diez A, et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. *Hepatology*. 2001;**34**(6):1158-63.
 114. Tsochatzidis E, Papatheodoridis GV, Manesis EK, Kafiri G, Tiniakos DG, Archimandritis AJ. Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis. *Aliment Pharmacol Ther*. 2008;**27**(11):80-9.
 115. Assy N, Kaita K, Mymin D, Levy C, Rosser B, Minuk G. Fatty infiltration of liver in hyperlipidemic patients. *Dig Dis Sci*. 2000;**45**(10):1929-34.
 116. Bolukbas FF, Bolukbas C, Zeyrek F, Aslan M, Bahcecioglu HI, Ozardali I. High rate of seropositivity of Chlamydia pneumoniae IgA in male patients with nonalcoholic steatohepatitis. *Dig Dis Sci*. 2005;**50**(6):1141-5.
 117. Lonardo A, Bellini M, Tondelli M, Frazzoni M, Grisendi A, Pulvirenti M, et al. Nonalcoholic steatohepatitis and the "bright liver syndrome": should a recently expanded clinical entity be further expanded? *Am J Gastroenterol*. 1995;**90**(11):2072-4.
 118. Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary? *Eur J Gastroenterol Hepatol*. 2003;**15**(5):539-43.
 119. Mendler MH, Bouillet P, Le Sidaner A, Lavoine E, Labrousse F, Sautereau D, et al. Dual-energy CT in the diagnosis and quantification of fatty liver: limited clinical value in comparison to ultrasound scan and single-energy CT, with special reference to iron overload. *J Hepatol*. 1998;**28**(5):785-94.
 120. Fishbein MH, Gardner KG, Potter CJ, Schmalbrock P, Smith MA. Introduction of fast MR imaging in the assessment of hepatic steatosis. *Magn Reson Imaging*. 1997;**15**(3):287-93.
 121. Huang MA, Greenon JK, Chao C, Anderson L, Peterman D, Jacobson J, et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. *Am J Gastroenterol*. 2005;**100**(5):1072-81.
 122. Capristo E, Miele L, Forgione A, Vero V, Farnetti S, Mingrone G, et al. Nutritional aspects in patients with non-alcoholic steatohepatitis (NASH). *Eur Rev Med Pharmacol Sci*. 2005;**9**(5):265-8.
 123. Sato F, Tamura Y, Watada H, Kumashiro N, Igarashi Y, Uchino H, et al. Effects of diet-induced moderate weight reduction on intrahepatic and intramyocellular triglycerides and glucose metabolism in obese subjects. *J Clin Endocrinol Metab*. 2007;**92**(8):3326-9.
 124. Fisler JS, Drenick EJ. Starvation and semistarvation diets in the management of obesity. *Annu Rev Nutr*. 1987;**7**:465-84.
 125. Vajro P, Fontanella A, Perna C, Orso G, Tedesco M, De Vincenzo A. Persistent hyperaminotransferasemia resolving after weight reduction in obese children. *J Pediatr*. 1994;**125**(2):239-41.
 126. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. *Gastroenterology*. 1990;**99**(5):1408-13.
 127. Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. *Proc Natl Acad Sci U S A*. 1997;**94**(6):2557-62.
 128. Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. *J Hepatol*. 1997;**27**(1):103-7.
 129. Faggioni R, Fantuzzi G, Gabay C, Moser A, Dinarello CA, Feingold KR, et al. Leptin deficiency enhances sensitivity to endotoxin-induced lethality. *Am J Physiol*. 1999;**276**(1 Pt 2):R136-42.
 130. Chavin KD, Yang S, Lin HZ, Chatham J, Chacko VP, Hoek JB, et al. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. *J Biol Chem*. 1999;**274**(9):5692-700.
 131. Boss O, Muzzin P, Giacchino JP. The uncoupling proteins, a review. *Eur J Endocrinol*. 1998;**139**(1):1-9.
 132. Eriksson S, Eriksson KF, Bondesson L. Nonalcoholic steatohepatitis in obesity: a reversible condition. *Acta Med Scand*. 1986;**220**(1):83-8.
 133. Harris RB, Kor H. Insulin insensitivity is rapidly reversed in rats by reducing dietary fat from 40 to 30% of energy. *J Nutr*. 1992;**122**(9):1811-22.
 134. Ouyang X, Cirillo P, Sautin Y, McCall S, Bruchette JL, Diehl AM, et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. *J Hepatol*. 2008;**48**(6):993-9.
 135. Zivkovic AM, German JB, Sanyal AJ. Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. *Am J Clin Nutr*. 2007;**86**(2):285-300.
 136. Centis E, Marzocchi R, Di Domizio S, Ciaravella MF, Marchesini G. The effect of lifestyle changes in non-alcoholic fatty liver disease. *Dig Dis*. 2010;**28**(1):267-73.
 137. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and non-alcoholic steatohepatitis: Selected practical issues in their evaluation and management. *Hepatology*. 2009;**49**(1):306-17.
 138. Harrison SA, Ramrakhiani S, Brunt EM, Anbari MA, Cortese C, Bacon BR. Orlistat in the treatment of NASH: a case series. *Am J Gastroenterol*. 2003;**98**(4):926-30.
 139. Brolin RE. Bariatric surgery and long-term control of morbid obesity. *JAMA*. 2002;**288**(22):2793-6.
 140. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. *Hepatology*. 2009;**49**(1):80-6.
 141. Vemuri VK, Janero DR, Makriyannis A. Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome. *Physiol Behav*. 2008;**93**(4-5):671-86.
 142. Teixeira-Clerc F, Julien B, Grenard P, Tran Van Nhieu J, Deveaux V, Li L, et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. *Nat Med*. 2006;**12**(6):671-6.
 143. Gary-Bobo M, Elachouri G, Gallas JF, Janiak P, Marini P, Ravinet-Trillou C, et al. Rimobant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. *Hepatology*. 2007;**46**(1):122-9.
 144. Despres JP, Golay A, Sjostrom L. Effects of rimobant on metabolic risk factors in overweight patients with dyslipidemia. *N Engl J Med*. 2005;**353**(20):2121-34.
 145. Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. *J Hepatol*. 2001;**35**(1):134-46.
 146. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. *Hepatology*. 1996;**23**(6):1464-7.
 147. Guma G, Viola L, Thome M, Galdame O, Alvarez E. Ursodeoxycholic acid in the treatment of nonalcoholic steatohepatitis: results of a prospective clinical controlled trial. *Hepatology*. 1997;**26**(Part 2):387A.
 148. Ceriani R, Bunati S, Morini L, Sacchi E, Colombo G. Effect of ursodeoxycholic acid plus diet in patients with non-alcoholic steatohepatitis. *Hepatology*. 1998;**28**(Part 2):386A.
 149. Kiyici M, Gulen M, Gurel S, Nak SG, Dolar E, Savci G, et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. *Can J Gastroenterol*. 2003;**17**(12):713-8.
 150. Méndez-Sánchez N, González V, Chávez-Tapia N, Ramos M, Uribe M. Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease. A double-blind, placebo-controlled trial. *Ann Hepatol*. 2004;**3**(3):108-12.
 151. Orlando R, Azzalini L, Orando S, Lirussi F. Bile acids for non-alcoholic fatty liver disease and/or steatohepatitis. *Cochrane Database Syst Rev*. 2007;(1):CD005160.
 152. Vajro P, Franzese A, Valerio G, Iannucci MP, Aragione N. Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children. *J Pediatr*. 2000;**136**(6):739-43.
 153. Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. *Hepatology*. 2004;**39**(3):770-8.
 154. Obinata K, Maruyama T, Hayashi M, Watanabe T, Nittono H. Effect of taurine on the fatty liver of children with simple obesity. *Adv Exp Med*

- Biol. 1996;**403**:607-13.
155. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of nonalcoholic fatty liver disease with insulin resistance. *Am J Med.* 1999;**107**(5):450-5.
 156. Vozarova B, Stefan N, Lindsay RS, Saremi A, Pratley RE, Bogardus C, et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. *Diabetes.* 2002;**51**(6):1889-95.
 157. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. *Ann Intern Med.* 2002;**137**(1):25-33.
 158. Kral JG, Thung SN, Biron S, Hould FS, Lebel S, Marceau S, et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. *Surgery.* 2004;**135**(1):48-58.
 159. Hattori Y, Suzuki K, Hattori S, Kasai K. Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. *Hypertension.* 2006;**47**(6):1183-8.
 160. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. *Nat Med.* 2000;**6**(9):998-1003.
 161. Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. *Cochrane Database Syst Rev.* 2007;(1):CD005166.
 162. Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. *Aliment Pharmacol Ther.* 2004;**19**(5):537-44.
 163. Tiikkainen M, Hakkinen AM, Korshennikova E, Nyman T, Makimattila S, Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. *Diabetes.* 2004;**53**(8):2169-76.
 164. Bugianesi E, Gentilecore E, Manini R, Natale S, Vanni E, Villanova N, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. *Am J Gastroenterol.* 2005;**100**(5):1082-90.
 165. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med.* 2002;**346**(6):393-403.
 166. Loomba R, Lutchman G, Kleiner DE, Ricks M, Feld JJ, Borg BB, et al. Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. *Aliment Pharmacol Ther.* 2009;**29**(2):172-82.
 167. Schwimmer JB, Middleton MS, Deutsch R, Lavine JE. A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis. *Aliment Pharmacol Ther.* 2005;**21**(7):871-9.
 168. Gastaldelli A, Harrison SA, Belfort-Aguilar R, Hardies LJ, Balas B, Schenker S, et al. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. *Hepatology.* 2009;**50**(4):1087-93.
 169. Caldwell SH, Hespdenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. *Am J Gastroenterol.* 2001;**96**(2):519-25.
 170. Henriksen JH, Ring-Larsen H. Rosiglitazone: possible complications and treatment of non-alcoholic steatohepatitis (NASH). *J Hepatol.* 2008;**48**(1):174-6.
 171. Watkins PB. Insight into hepatotoxicity: The troglitazone experience. *Hepatology.* 2005;**41**(2):229-30.
 172. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. *Hepatology.* 2004;**39**(1):188-96.
 173. Azuma T, Tomita K, Kato S, Adachi M, Inokuchi N, Kitamura N, et al. A pilot study of a thiazolidinedione, pioglitazone, in nonalcoholic steatohepatitis. *Hepatology.* 2002;**36**(4).
 174. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. *N Engl J Med.* 2006;**355**(22):2297-307.
 175. Shadid S, Jensen MD. Effect of pioglitazone on biochemical indices of non-alcoholic fatty liver disease in upper body obesity. *Clin Gastroenterol Hepatol.* 2003;**1**(5):384-7.
 176. Sanyal AJ, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling RK, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. *Clin Gastroenterol Hepatol.* 2004;**2**(12):1107-15.
 177. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. *Gastroenterology & Hepatology.* 2008;**20**:1252-5.
 178. Oruc N, Dereli D, Batur Y, Yilmaz C, Yuce G, Gunsar F, et al. Beneficial effects of insulin sensitizing agents on fatty liver disease; preliminary results. *J Hepatol.* 2003;**38**(suppl 2):198-9.
 179. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Sponseller CA, Hampton K, Bacon BR. Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. *J Hepatol.* 2003;**38**(4):434-40.
 180. Balas B, Belfort R, Harrison SA, Darland C, Finch J, Schenker S, et al. Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. *J Hepatol.* 2007;**47**(4):565-70.
 181. Diamant M, Heine RJ. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. *Drugs.* 2003;**63**(13):1373-405.
 182. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. *Diabetes Care.* 2004;**27**(1):256-63.
 183. Lutchman G, Modi A, Kleiner DE, Promrat K, Heller T, Ghany M, et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. *Hepatology.* 2007;**46**(2):424-9.
 184. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. *J Hepatol.* 1999;**31**(2):384.
 185. Saibara T, Onishi S, Ogawa Y, Yoshida S, Enzan H. Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis. *Lancet.* 1999;**353**(9166):1802.
 186. Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. *Hepatology.* 2005;**41**(4):690-5.
 187. Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. *Gastroenterology.* 2004;**126**(5):1287-92.
 188. Lewis JH, Mortensen ME, Zweig S, Fusco MJ, Medoff JR, Belder R. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. *Hepatology.* 2007;**46**(5):1453-63.
 189. Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. *Am J Med Sci.* 2005;**329**(2):62-5.
 190. Hatzitolios A, Savopoulos C, Lazaraki G, Sidiropoulos I, Haritanti P, Lefkopoulou A, et al. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. *Indian J Gastroenterol.* 2004;**23**(4):131.
 191. Gomez-Dominguez E, Gisbert JP, Moreno-Monteagudo JA, Garcia-Buey L, Moreno-Otero R. A pilot study of atorvastatin treatment in dyslipidemic, non-alcoholic fatty liver patients. *Aliment Pharmacol Ther.* 2006;**23**(11):1643-7.
 192. Rallidis LS, Drakoulis CK, Parasi AS. Pravastatin in patients with non-alcoholic steatohepatitis: results of a pilot study. *Atherosclerosis.* 2004;**174**(1):193-6.
 193. Sofi F, Giangrandi I, Cesari F, Corsani I, Abbate R, Gensini GF, et al. Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study. *Int J Food Sci Nutr.* 2010;**61**(8):792-802.
 194. Georgescu EF, Georgescu M. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. *J Gastrointest Liver Dis.* 2007;**16**(1):39-46.
 195. Levy JR, Clore JN, Stevens W. Dietary n-3 polyunsaturated fatty acids decrease hepatic triglycerides in Fischer 344 rats. *Hepatology.* 2004;**39**(3):608-16.
 196. Decsi T, Molnar D, Koletzko B. Reduced plasma concentrations of alpha-tocopherol and beta-carotene in obese boys. *J Pediatr.* 1997;**130**(4):653-5.
 197. Strauss RS. Comparison of serum concentrations of alpha-tocopherol and beta-carotene in a cross-sectional sample of obese and nonobese children (NHANES III). National Health and Nutrition Examination Survey. *J Pediatr.* 1999;**134**(2):160-5.
 198. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. *J Pediatr.* 2000;**136**(6):734-8.
 199. Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. *Aliment Pharmacol Ther.* 2001;**15**(10):1667-72.
 200. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. *Am J Gastroenterol.* 2003;**98**(11):2485-90.
 201. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. *Hepatology.* 2003;**38**(2):413-9.
 202. Federico A, Trappoliere M, Tuccillo C, de Sio I, Di Leva A, Del Vecchio Blanco C, et al. A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations. *Gut.* 2006;**55**(6):901-2.

203. Sanyal A, Contos M, Sargeant C, Stravitz R, Luketic V, Sterling R, et al. A randomized controlled pilot study of pioglitazone and vitamin E versus vitamin E for nonalcoholic steatohepatitis. *Hepatology*. 2002;**36**:382A.
204. Gulbahar O, Karasu ZA, Ersoz G, Akarca US, Musoglu A. Treatment of non-alcoholic steatohepatitis with N-acetyl cystein. *Gastroenterology*. 2000;**118**(4):A1444.
205. Pamuk GE, Sonsuz A. N-acetylcysteine in the treatment of non-alcoholic steatohepatitis. *J Gastroenterol Hepatol*. 2003;**18**(10):1220-1.
206. Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. *Am J Gastroenterol*. 2001;**96**(9):2711-7.
207. Miglio F, Rovati LC, Santoro A, Setnikar I. Efficacy and safety of oral betaine glucuronate in non-alcoholic steatohepatitis. A double-blind, randomized, parallel-group, placebo-controlled prospective clinical study. *Arzneimittelforschung*. 2000;**50**(8):722-7.
208. Khoshbaten M, Aliasgarzadeh A, Masnadi K, Tarzamani MK, Farhang S, Babaei H, et al. N-Acetylcysteine Improves Liver Function in Patients with Non-Alcoholic Fatty Liver Disease. *Hepat Mon*. 2010;**10**(1):12-6.
209. Lirussi F, Azzalini L, Orando S, Orlando R, Angelico F. Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. *Cochrane Database Syst Rev*. 2007;(1):CD004996.
210. Yoneda M, Fujita K, Nozaki Y, Endo H, Takahashi H, Hosono K, et al. Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: An open-label, pilot study. *Hepatol Res*. **40**(6):613-21.
211. Lirussi F, Mastropasqua E, Orando S, Orlando R. Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis. *Cochrane Database Syst Rev*. 2007;(1):CD005165.
212. Koca SS, Bahcecioglu IH, Poyrazoglu OK, Ozercan IH, Sahin K, Usundag B. The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet. *Inflammation*. 2008;**31**(2):91-8.
213. Satapathy SK, Sakhuja P, Malhotra V, Sharma BC, Sarin SK. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. *J Gastroenterol Hepatol*. 2007;**22**(5):634-8.
214. Merat S, Aduli M, Kazemi R, Sotoudeh M, Sedighi N, Sohrabi M, et al. Liver histology changes in nonalcoholic steatohepatitis after one year of treatment with probucol. *Dig Dis Sci*. 2008;**53**(8):2246-50.
215. Hajjaghahmohammadi A, Ziaee A, Rafiei R. The Efficacy of Silymarin in Decreasing Transaminase Activities in Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial. *Hepat Mon*. 2008;**8**(3):191-5.
216. Hashemi SJ, Hajjani E, Haidari Sardabi E. A Placebo-Controlled Trial of Silymarin in Patients with Nonalcoholic Fatty Liver Disease. *Hepat Mon*. 2009;**9**(4):265-70.
217. Younossi ZM, Gramlich T, Bacon BR, Matteoni CA, Boparai N, O'Neill R, et al. Hepatic iron and nonalcoholic fatty liver disease. *Hepatology*. 1999;**30**(4):847-50.
218. Facchini FS, Hua NW, Stoohs RA. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. *Gastroenterology*. 2002;**122**(4):931-9.
219. Mottin CC, Moretto M, Padoin AV, Swarowsky AM, Toneto MG, Glock L, et al. The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. *Obes Surg*. 2004;**14**(5):635-7.
220. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. *Gastroenterology*. 2001;**121**(1):91-100.
221. Luyckx FH, Desai C, Thiry A, Dewe W, Scheen AJ, Gielen JE, et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. *Int J Obes Relat Metab Disord*. 1998;**22**(3):222-6.
222. Klein S, Mittendorfer B, Eagon JC, Patterson B, Grant L, Feirt N, et al. Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. *Gastroenterology*. 2006;**130**(6):1564-72.
223. Barker KB, Palekar NA, Bowers SP, Goldberg JE, Pulcini JP, Harrison SA. Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. *Am J Gastroenterol*. 2006;**101**(2):368-73.
224. Dixon JB. Surgical treatment for obesity and its impact on non-alcoholic steatohepatitis. *Clin Liver Dis*. 2007;**11**(1):141-54, ix-x.
225. Furuya CK, Jr., de Oliveira CP, de Mello ES, Faintuch J, Raskovski A, Matsuda M, et al. Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years. *J Gastroenterol Hepatol*. 2007;**22**(4):510-4.
226. Campbell JM, Hunt TK, Karam JH, Forsham PH. Jejunoileal bypass as a treatment of morbid obesity. *Arch Intern Med*. 1977;**137**(5):602-10.
227. Weiner RA. Surgical treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease. *Dig Dis*. **28**(1):274-9.
228. Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. *Cochrane Database Syst Rev*. 2010;**20**(1):CD007340.